Presence of retinopathy and incident kidney and cardiovascular events in type 2 diabetes with normoalbuminuria – A post-hoc analysis of the PRIORITY randomized clinical trial

on the behalf of the PRIORITY Study Group, Viktor Rotbain Curovic*, Nete Tofte, Morten Lindhardt, Katarina Adamova, Stephan J.L. Bakker, Joachim Beige, Joline W.J. Beulens, Andreas L. Birkenfeld, Gemma Currie, Christian Delles, Ingo Dimos, Lidmila Francová, Marie Frimodt-Møller, Peter Girman, Rüdiger Göke, Tine W. Hansen, Tereza Havrdova, Adriaan Kooy, Gozewijnw D. LavermanHarald Mischak, Gerjan Navis, Giel Nijpels, Marina Noutsou, Alberto Ortiz, Aneliya Parvanova, Frederik Persson, John R. Petrie, Piero L. Ruggenenti, Femke Rutters, Ivan Rychlík, Justyna Siwy, Goce Spasovski, Marijn Speeckaert, Matias Trillini, Petra Zürbig, Heiko von der Leyen, Peter Rossing

*Bijbehorende auteur voor dit werk

OnderzoeksoutputAcademicpeer review

1 Citaat (Scopus)
20 Downloads (Pure)

Samenvatting

Aims: Baseline diabetic retinopathy (DR) and risk of development of microalbuminuria, kidney function decline, and cardiovascular events (CVEs) in type 2 diabetes. Methods: Post-hoc analysis of the PRIORITY study including 1758 persons with type 2 diabetes and normoalbuminuria followed for a median of 2.5 (IQR: 2.0–3.0) years. DR diagnosis included non-proliferative and proliferative abnormalities, macular oedema, or prior laser treatment. Cox models were fitted to investigate baseline DR presence with development of persistent microalbuminuria (urinary albumin-creatinine ratio > 30 mg/g); chronic kidney disease (CKD) G3 (eGFR <60 ml/min/1.73m2); and CVE. Models were adjusted for relevant risk factors. Results: At baseline, 304 (17.3 %) had DR. Compared to persons without DR, they were older (mean ± SD: 62.7 ± 7.7 vs 61.4 ± 8.3 years, p = 0.019), had longer diabetes duration (17.9 ± 8.4 vs. 10.6 ± 7.0 years, p < 0.001), and higher HbA1c (62 ± 13 vs. 56 ± 12 mmol/mol, p < 0.001). The adjusted hazard ratios of DR at baseline for development of microalbuminuria (n = 197), CKD (n = 166), and CVE (n = 64) were: 1.50 (95%CI: 1.07, 2.11), 0.87 (95%CI: 0.56, 1.34), and 2.61 (95%CI: 1.44, 4.72), compared to without DR. Conclusions: Presence of DR in normoalbuminuric type 2 diabetes was associated with an increased risk of developing microalbuminuria and CVE, but not with kidney function decline.

Originele taal-2English
Artikelnummer108433
Aantal pagina's19
TijdschriftJOURNAL OF DIABETES AND ITS COMPLICATIONS
Volume37
Nummer van het tijdschrift4
DOI's
StatusPublished - apr.-2023

Citeer dit